Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

计划入组 32 人 · 首次发布于 2024 年 4 月 16 日

Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

计划入组 32 人 · 首次发布于 2011 年 2 月 17 日

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

计划入组 83 人 · 首次发布于 2017 年 10 月 2 日

thyroid-stimulating hormone receptor antagonist (graves disease/thyroid eye disease)

Thyroid Eye Disease(EyebioKorea)

Thyroid eye disease(RevOpsis)

LIONS EYE INSTITUTE LIMITED

Australia

Shanghai Eye Disease Prevention and Treatment Center

China

Rare Disease Research, LLC

Novel Chimeric Autoantibody Receptor T Cells Show Promise for Treating Graves' Disease

EMA Recommends Approval of Tepezza for Thyroid Eye Disease, First Targeted Treatment in EU

Ethyreal Bio Launches With $101 Million to Advance Dual-Targeting TSHR Antibody for Graves' Disease and Thyroid Eye Disease